Deep Blue Biotech Ltd

Developing lower-carbon specialty chemicals using genetically engineered photosynthetic cyanobacteria.

Cover Block

Publicly reported

Field	Detail
Company	Deep Blue Biotech Ltd
Tagline	Developing lower-carbon specialty chemicals using genetically engineered photosynthetic cyanobacteria.
Headquarters	London, England [Companies House, May 2023]
Founded	2023 [Companies House, May 2023]
Stage	Pre-Seed [TechCrunch, November 2024]
Business Model	B2B
Industry	Cleantech / Climatetech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+): Manuel Rios Krauss, Tim Corcoran, Andrej Ondráčka [TechCrunch, November 2024] [Strategic Allies, March 2024]
Funding Label	Pre-seed
Total Disclosed	~$800,000 [TechCrunch, November 2024]

Summary and Signal

PUBLIC Deep Blue Biotech is a UK synthetic-biology startup developing lower-carbon specialty chemicals with genetically engineered photosynthetic cyanobacteria, and it merits investor attention because it is trying to enter a premium ingredients market with a carbon-focused manufacturing thesis already credible enough to attract early institutional backing and grant support [TechCrunch, November 2024] [deepbluebiotech.com] [MassChallenge, June 2025]. The company was incorporated in May 2023, and the founding story is relatively clear: Manuel Rios Krauss, Tim Corcoran, and Andrej Ondráčka met through the Carbon13 Venture Builder programme, then formed the business around photosynthesis-based biomanufacturing rather than conventional fossil-derived chemical production [Companies House, May 2023] [Strategic Allies, March 2024].

Its initial commercial wedge is hyaluronic acid for beauty, personal-care, health, and wellness applications, produced from CO2, sunlight, and seawater-based nutrients; that positioning matters because it starts with a high-value ingredient where sustainability claims and input economics can matter more than in bulk chemicals, although public evidence does not yet establish commercial scale or unit-cost performance [deepbluebiotech.com] [TechCrunch, November 2024]. On team quality, the strongest public signal is at the CEO level: TechCrunch identified Manuel Rios Krauss as a former Unilever vice president of sustainable design, while the broader founding group combines business development and molecular-genetics experience that fits an early platform company, if still at an early execution stage [TechCrunch, November 2024] [deepbluebiotech.com] [Strategic Allies, March 2024].

Funding remains modest but real. TechCrunch reported an $800,000 pre-seed led by Sustainable Ventures in November 2024, with participation from One Planet Capital, PCSI, and SFC Capital, and the same coverage said the company had secured two Innovate UK grants; later local coverage in October 2026 said total investment had risen to just over £1.2 million, including a £400,000 innovation grant and private investment [TechCrunch, November 2024] [Sheffield Technology Parks, October 2026]. The business model is B2B, and the near-term test is whether Deep Blue can convert early technical credibility into paid pilots, joint development agreements, and eventually repeatable ingredient supply relationships, none of which are yet named publicly [TechCrunch, November 2024].

Over the next 12 to 18 months, the points worth watching are straightforward: proof that hyaluronic acid output can move from lab promise to customer-qualified product, evidence that the process economics hold outside controlled settings, and signs that the platform can extend beyond a single premium ingredient without stretching capital needs too quickly [MassChallenge, June 2025] [Sheffield Technology Parks, September 2026] [PitchBook].

One source, partially checked -- This section relies on Companies House, TechCrunch, the company website, Strategic Allies, MassChallenge, and Sheffield Technology Parks; core company identity, founding, and pre-seed funding are corroborated, but product-performance and later funding details remain partly company-linked or single-source.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Cleantech / Climatetech
Technology Type	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Pre-seed, total disclosed ~$800,000 [TechCrunch, November 2024]

Company Overview

PUBLIC Deep Blue Biotech Ltd is a London-based UK synthetic-biology startup incorporated on 31 May 2023, focused on producing lower-carbon specialty chemicals with genetically engineered photosynthetic cyanobacteria [Companies House, May 2023] [deepbluebiotech.com, retrieved 2024]. In plain terms, the company is trying to use CO₂, sunlight, and seawater-based nutrients as production inputs for chemicals that are usually made through more carbon-intensive routes [deepbluebiotech.com, retrieved 2024].

The public record is still early, but the chronology is reasonably clear. Companies House shows the legal entity was formed in May 2023 [Companies House, May 2023]. The company website positions hyaluronic acid as the initial product focus, aimed at beauty, personal-care, health, and wellness applications, alongside a broader ambition to replace fossil-fuel-derived chemicals over time [deepbluebiotech.com, retrieved 2024].

By late 2024, Deep Blue had moved from formation to external financing. The company announced an $800,000 pre-seed round in November 2024, and its website presents the business as a B2B specialty-chemicals platform rather than a direct-to-consumer brand [Crunchbase, retrieved 2026] [deepbluebiotech.com, retrieved 2024]. That sequence matters because it suggests the company had already settled on both its first commercial wedge and its operating model within roughly 18 months of incorporation.

One source, partially checked -- Confirmed by Companies House and the company website, with funding stage context supported by Crunchbase.

The Product and the Stack

Core approach

MIXED The technical claim worth anchoring on is simple enough to state and still unusual in practice: Deep Blue Biotech says it uses genetically engineered photosynthetic cyanobacteria to make specialty chemicals from CO2, sunlight, and seawater-based nutrients, rather than conventional fossil-derived feedstocks [TechCrunch, November 2024] [deepbluebiotech.com, retrieved 2024]. Across public descriptions, that platform is framed as a synthetic-biology production system for lower-carbon chemicals, with photosynthesis doing the metabolic work that petrochemical inputs or sugar-fed fermentation often do elsewhere [PitchBook, retrieved 2026] [Benchscope, retrieved 2026]. The company has not publicly disclosed process yields, reactor design, strain performance, or downstream purification details in the cited materials, so the technical read here rests on platform description rather than independently verified operating data.

Initial product focus

MIXED The first disclosed product is hyaluronic acid, aimed at beauty, personal-care, health, and wellness applications [deepbluebiotech.com, retrieved 2024] [Science Creates, retrieved 2024]. That choice is strategically coherent on public evidence: TechCrunch reported that the company was beginning with beauty and cosmetics buyers, and Sheffield Technology Parks separately tied the company to a hyaluronic-acid program as it expanded lab operations [TechCrunch, November 2024] [Sheffield Technology Parks, September 2026]. Publicly circulated claims that the process can be carbon-neutral, lower-cost, scalable, or potentially low in capital expenditure should be read as company or program-level positioning rather than validated performance benchmarks, because the available sources do not publish side-by-side cost, emissions, or throughput data [MassChallenge, June 2025] [Cosmetics Labels, retrieved 2026].

One source, partially checked -- Core product claims are corroborated by TechCrunch and the company website, but technical performance and economics remain described mainly through company and accelerator materials.

The Market They Are Entering

PUBLIC The market matters now because Deep Blue Biotech is trying to enter two demand pools at once, specialty ingredients and lower-carbon chemical inputs, and both are being shaped by buyer pressure to cut embedded emissions without rewriting end products from scratch [TechCrunch, November 2024] [MassChallenge, June 2025].

The constraint in this section is straightforward: the available source set does not provide a cited third-party TAM, SAM, or SOM for Deep Blue itself, and there is no named external market report in the record quantifying the addressable market for photosynthesis-based specialty chemicals or cyanobacteria-derived hyaluronic acid. What is visible from public reporting is the company's market entry logic. It starts with hyaluronic acid for beauty, personal-care, health, and wellness products, then points to a broader specialty-chemicals platform built on genetically engineered photosynthetic cyanobacteria using CO₂, sunlight, and seawater-based nutrients [deepbluebiotech.com, retrieved 2024] [TechCrunch, November 2024]. That sequencing suggests a beachhead in higher-value ingredients, where premium pricing and sustainability claims can matter more than in bulk chemicals, but the market size itself is not quantified in the cited evidence.

Demand signals in the record are also early, but they are directionally consistent. TechCrunch reported in November 2024 that the company's pre-seed financing was intended to fund first paid pilots and joint-development agreements for customers looking to incorporate its hyaluronic acid into products, while Strategic Allies reported earlier-stage letters of intent without naming counterparties [TechCrunch, November 2024] [Strategic Allies, March 2024]. Those are not revenue disclosures, and they do not establish repeat purchasing, but they do indicate that potential buyers are at least willing to test whether a lower-carbon input can meet formulation and cost requirements.

Adjacent markets matter because Deep Blue is not only selling a molecule, it is testing an alternative production method against incumbent petrochemical and fermentation routes. Public descriptions place the company at the intersection of personal-care ingredients, industrial biotechnology, and broader decarbonization of chemical manufacturing [PitchBook] [Cosmetics Labels] [Crunchbase]. If the platform performs as described, the practical substitute set is wider than hyaluronic acid alone: it includes other fossil-derived specialty ingredients and, in some cases, conventional bio-based production methods that still rely on sugar feedstocks or more resource-intensive inputs. The cited sources stop short of naming those substitute suppliers, but they consistently frame the company as part of a wider move toward lower-emission chemical production rather than a single-product skincare story [TechCrunch, November 2024] [MassChallenge, June 2025].

Regulatory and macro forces are supportive in a general sense, even if the source set does not tie Deep Blue to any one policy regime. The company has received Innovate UK grant support, according to TechCrunch, and Sheffield Technology Parks later reported a £400,000 innovation grant as part of funding that had reached just over £1.2 million by October 2026 [TechCrunch, November 2024] [Sheffield Technology Parks, October 2026]. Grant backing does not validate product-market fit, but it does suggest that public funding bodies see climate-oriented industrial biotech as a category worth subsidizing. At the buyer level, the repeated emphasis on lower-carbon, potentially lower-cost, and scalable production reflects a macro environment in which consumer brands and ingredient purchasers are under pressure to show progress on Scope 3 emissions and supply chain resilience, especially in personal care and wellness categories [MassChallenge, June 2025] [Cosmetics Labels].

Market lens	Public evidence	Interpretation
Beachhead segment	Initial product is hyaluronic acid for beauty, personal-care, health, and wellness products [deepbluebiotech.com, retrieved 2024]	Entry point appears to be a premium ingredient market where sustainability may command buyer attention before scale economics are fully proven.
Platform ambition	Broader goal is lower-carbon specialty chemicals made via photosynthetic cyanobacteria [TechCrunch, November 2024] [PitchBook]	The long-term market is wider than cosmetics, but the available sources do not size it.
Early demand formation	Funding intended to support first paid pilots and joint-development agreements; letters of intent also reported [TechCrunch, November 2024] [Strategic Allies, March 2024]	Public evidence supports early commercial testing, not established market penetration.
Policy and grant support	Two Innovate UK grants reported; later coverage cites a £400,000 innovation grant [TechCrunch, November 2024] [Sheffield Technology Parks, October 2026]	Non-dilutive funding is a positive category signal, though not a demand proxy on its own.

The table shows a market case built more on category logic than disclosed market data. For investors, that means the central question is not whether the sustainability narrative is legible, it is whether Deep Blue can convert that narrative into validated unit economics and repeat demand in a specialty ingredient niche first.

One source, partially checked -- Market interpretation is grounded in TechCrunch, company materials, and accelerator or ecosystem profiles, but the section lacks independent third-party TAM, SAM, or SOM data and relies partly on company-framed market positioning.

The Competitive Field

MIXED Deep Blue Biotech is not competing on a new end market so much as on a different production route, trying to sell familiar specialty chemicals into beauty and personal care through photosynthetic biomanufacturing rather than conventional fossil-derived or fermentation-based supply chains [TechCrunch, November 2024] [deepbluebiotech.com, retrieved 2024].

The competitive set splits into three layers, even if the public record does not yet name direct startup peers. The first layer is incumbent chemical and ingredient manufacturing, where hyaluronic acid and related specialty inputs are already supplied through established industrial processes and buyer relationships. The second layer is synthetic-biology challengers pursuing lower-carbon production pathways for chemicals more broadly, which is the lane Deep Blue itself describes through its cyanobacteria platform [PitchBook, retrieved 2026] [Benchscope, retrieved 2026]. The third layer is adjacent substitutes: formulators can keep buying conventionally sourced ingredients, or switch to other sustainability-marketed biomaterials, if Deep Blue cannot meet price, quality, or volume thresholds. That matters because the company is starting with hyaluronic acid, a product category buyers already understand, which lowers market-education risk but raises execution pressure against existing supply [deepbluebiotech.com, retrieved 2024] [Science Creates, retrieved 2024].

Where the company appears strongest today is in founder-market fit and narrative alignment with the initial buyer segment. Manuel Rios Krauss previously held senior sustainability and design roles at Unilever, and TechCrunch identified him as a former vice president of sustainable design there, which is a relevant background for selling into consumer-facing categories that care about ingredient provenance as well as performance [TechCrunch, November 2024]. The initial product choice also looks deliberate: hyaluronic acid is a premium ingredient in beauty and personal care, where a lower-carbon production story may carry more commercial weight than it would in lower-margin bulk chemicals [deepbluebiotech.com, retrieved 2024] [Sheffield Technology Parks, September 2026]. Still, that edge looks perishable unless it converts into customer programs, repeatable quality data, and scaled manufacturing proof. Public reporting mentions planned paid pilots, joint development agreements, and earlier letters of intent, but it does not name customers or show completed commercial deployments [TechCrunch, November 2024] [Strategic Allies, March 2024].

The main exposure is less a named startup rival than the entrenched advantages of incumbent supply. Deep Blue has disclosed a relatively small pre-seed round of $800,000 led by Sustainable Ventures, plus two Innovate UK grants with undisclosed sizes at that point, which is enough to advance lab work but not enough on its own to establish manufacturing leadership in a process-intensive category [TechCrunch, November 2024]. Public descriptions from MassChallenge and the company emphasize carbon-neutral, lower-cost, scalable production and potentially low capital expenditure, but those claims remain company- or program-level assertions rather than field-validated benchmarks against incumbent producers [MassChallenge, June 2025] [deepbluebiotech.com, retrieved 2024]. In practice, that leaves the company exposed on three fronts: process scale-up, qualification by brand customers, and the possibility that buyers treat sustainability as a preference rather than a purchase driver if performance or unit economics lag.

The most plausible 18-month scenario is a sorting period rather than a winner-take-all market break. If Deep Blue can translate its pre-seed financing and grant support into named pilots, reproducible product quality, and early offtake in beauty and personal care, Deep Blue is the most plausible winner in its own disclosed lane because it already has a defined wedge product and founder credibility with sustainability-oriented consumer brands [TechCrunch, November 2024] [deepbluebiotech.com, retrieved 2024]. If, instead, customer validation stays unnamed and the platform remains framed mainly through accelerator and company descriptions, incumbent ingredient suppliers are the likely winners by default, simply because buyers can remain with proven sources while lower-carbon alternatives mature. With no publicly named direct competitor in the source set, the near-term contest is best understood as Deep Blue versus incumbent inertia rather than Deep Blue versus a clearly disclosed startup peer.

One source, partially checked -- This section relies on TechCrunch, Companies House-adjacent company materials, accelerator profiles, and company website claims. The core facts on funding, founders, and product focus are publicly sourced, but no named direct competitors or independently verified commercial benchmarks appear in the available public record.

Opportunity

Upside Case

PUBLIC The prize here is not a better skincare ingredient supplier, but a credible route to a new manufacturing platform for specialty chemicals that uses sunlight, CO2, and seawater-based nutrients instead of fossil-derived feedstocks, starting with a high-value product that can tolerate early scale constraints [TechCrunch, November 2024] [deepbluebiotech.com, retrieved 2024].

The headline opportunity is reasonably specific. Deep Blue Biotech is beginning with hyaluronic acid, a premium ingredient used in beauty and personal care, while building around genetically engineered photosynthetic cyanobacteria as the production chassis [deepbluebiotech.com, retrieved 2024] [Science Creates, retrieved 2024] [TechCrunch, November 2024]. That matters because hyaluronic acid is a narrower, commercially legible wedge than a broad claim to decarbonize chemicals, and the company has already attracted specialist climate and early-stage investors, two Innovate UK grants, and accelerator selection from Carbon13 and MassChallenge Switzerland, which together suggest the concept has cleared at least an initial technical and commercial screen [TechCrunch, November 2024] [Strategic Allies, March 2024] [MassChallenge, June 2025]. If the process works outside the lab, the reachable outcome is a category-defining specialty-chemicals platform that first wins in beauty and wellness, then extends to adjacent high-value molecules produced on the same biological stack [PitchBook, retrieved 2026] [Benchscope, retrieved 2026].

The upside paths are still conditional, but they are not abstract.

Scenario	What happens	Catalyst	Why it's plausible
Premium ingredient beachhead	Deep Blue becomes a differentiated supplier of lower-carbon hyaluronic acid into beauty, personal care, and wellness brands	Conversion of planned paid pilots and joint development work into repeat commercial supply agreements [TechCrunch, November 2024]	The company has already positioned hyaluronic acid as its initial product and said pre-seed funding would support first paid pilots with customers in this segment [deepbluebiotech.com, retrieved 2024] [TechCrunch, November 2024]
Platform expansion across specialty chemicals	The company uses the same cyanobacteria platform to add adjacent high-value ingredients after proving one commercial molecule	Demonstrated success with first-product manufacturing and customer acceptance, followed by new product programs on the same photosynthetic platform [PitchBook, retrieved 2026] [MassChallenge, June 2025]	Multiple public sources describe the business as a broader synthetic-biology or photosynthesis-based platform for specialty chemicals, not a single-product company [PitchBook, retrieved 2026] [Cosmetics Labels, retrieved 2026]
Capital-efficient biomanufacturing partner	Deep Blue becomes an attractive development and manufacturing partner for incumbents seeking lower-carbon input molecules without building in-house photosynthetic biology capabilities	A strategic partnership with a beauty, chemicals, or consumer-goods incumbent, likely around co-development or supply validation [TechCrunch, November 2024]	The founding team blends commercial brand experience from Unilever with molecular-genetics capability, and the company has already reported letters of intent and plans for joint development agreements, which is the early shape such a partnership path would take [TechCrunch, November 2024] [Strategic Allies, March 2024]

The compounding logic is straightforward if the first market lands. One successful molecule can de-risk the organism engineering, process design, regulatory work, and customer qualification burden for the next molecule, while every additional commercial program gives the company more evidence on yield, purity, cost, and buyer requirements. Public reporting does not yet establish that this flywheel is running at scale, but there are early signs of motion: Deep Blue has raised pre-seed capital, secured two Innovate UK grants, reported letters of intent, and by late 2026 had expanded into a double laboratory after bringing total investment to just over 3.2 million equivalent in disclosed and reported funding, including a 400,000 innovation grant and private investment [TechCrunch, November 2024] [Strategic Allies, March 2024] [Sheffield Technology Parks, October 2026]. In this model, commercial learning compounds with technical learning, and a company that starts as a single-ingredient supplier can become a repeatable developer of premium, lower-carbon inputs.

The size of the win is best framed as a scenario, not a forecast, because no credible market-sizing data or close public comparable is established in the available source set. Even so, the outer bound is meaningful: if Deep Blue proves that photosynthetic cyanobacteria can reliably produce one premium ingredient at commercial quality, then extends that system into a portfolio of specialty chemicals, the company could plausibly become a strategic platform asset for large beauty, ingredients, or chemicals groups seeking lower-carbon supply chains (scenario, not a forecast) [TechCrunch, November 2024] [MassChallenge, June 2025]. The evidence base today supports a real option on platform value, not proof of it. That is still a substantial upside case for a company that remains early, because the step from one validated molecule to several can matter more than the first product revenue line in determining eventual enterprise value.

One source, partially checked -- Based primarily on TechCrunch, company materials, accelerator profiles, and Sheffield Technology Parks; upside scenarios are analytical and conditional rather than observed outcomes.

Sources